Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006

Summary

This is a follow-up study to assess safety and clinical activity of continued AFFITOPE® AD02 vaccinations in patients with Alzheimer's disease. Patients, who have already participated in AFF006 will be involved in 27 study sites in Europe. Duration of patient's participation in the clinical trial is 19 months.

Timeline

Start

2013-06

Primary completion

2014-09

Completion

2014-09

Outcome

Outcome not reported

Stopped: “Study AFF006A was early terminated by the sponsor based on the results of study AFF006.”

Drugs

Indications